New eye drop treatments to protect vision in glaucoma patients
Topical drug delivery formulations for neuroprotection in glaucoma
This study is testing new eye drops that could help protect your vision by delivering special medicines directly to your eyes, making it easier to manage glaucoma and possibly slow down its effects on your eyesight.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11041117 on NIH RePORTER |
What this research studies
This research focuses on developing innovative eye drop formulations that can deliver neuroprotective drugs directly to the eye to help preserve retinal ganglion cells (RGC) in patients with glaucoma. By screening thousands of compounds, the team has identified promising candidates that not only lower intraocular pressure but also promote the survival of RGCs, which are crucial for vision. The study utilizes a novel thermosensitive gel-forming delivery system that enhances drug penetration into the eye, allowing for effective treatment with less frequent dosing. Patients may benefit from improved visual outcomes and potentially slower progression of their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glaucoma who are experiencing vision loss despite current treatments.
Not a fit: Patients who do not have glaucoma or those whose vision loss is unrelated to retinal ganglion cell damage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that significantly improve vision preservation for glaucoma patients.
How similar studies have performed: Previous research has shown promise in using similar drug delivery methods for ocular conditions, indicating potential for success in this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Ensign, Laura — Johns Hopkins University
- Study coordinator: Ensign, Laura
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.